• Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play
• Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinic
• Merck enlists antibody hunter Infinimmune for $838M biobucks pact

• Mapping the Trillion-Gene Universe: The Startup That Wants to Teach AI the Language of Life
• Why Data Infrastructure Determines AI Success in Drug Discovery
• PhenoTips, Health Institutions Launch C$5.4M AI Genomic Medicine Initiative in Canada

AstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flops

Lilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75B

Merck dives into detailed phase 3 data showing PCSK9 pill easily outswims rivals

• The Value of Prediction, and Cost of Success, in Drug Hunting
• Merck hands over $20M in IBD drug target deal with Flagship's Quotient
• The N-of-1 Revolution in Personalized Medicine

- Merck, girding for Keytruda cliff, flies toward promising CML asset with $6.7B Terns acquisition

- OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline

- Sarepta's big bet on Arrowhead's siRNA assets yields early data

• Baylor College of Medicine Taps Nautilus’ Voyager for Cancer Proteomics
• The Download: OpenAI is building a fully automated researcher, and a psychedelic trial blind spot
• From scientist to bioinformatician: how AI coding tools dissolved the activation energy barrier
  

• Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial
• STAT+: A biotech turns to Apple Watch to study its Parkinson’s drug
• Which FDA Division Has the Most Stability As AI Tools Get Adopted Across the Agency?

• With its first AI mod­el re­lease, Xaira tests scal­ing laws in vir­tu­al cells
• NVIDIA GTC 2026: Agentic AI Inflection Hits Healthcare and Life Sciences
• DOE Announces $293M Funding Opportunity as Genesis Mission Moves Toward Operational Phase

• Pfizer's hotly tipped breast cancer prospect delivers phase 2 win
• Aspen's 1-year data for Parkinson's cell therapy plant seeds for phase 3 trial
• Crossbow hits $77M series B round to bankroll quiver of T-Bolts

• Roche inks Nvidia deal to bolster AI factory, speed drug and diagnostic development
• Why most labs are not ready for AI: Cenevo shares what must change
• French AI Startup Building World Models Raises $1.03 billion